Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IKT
DateTimeSourceHeadlineSymbolCompany
06/12/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IKTInhibikase Therapeutics Inc
06/12/202408:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
06/12/202408:47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IKTInhibikase Therapeutics Inc
03/12/202422:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
19/11/202408:49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
19/11/202408:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
15/11/202400:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
09/11/202408:07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
29/10/202408:26Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
29/10/202407:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
26/10/202408:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
26/10/202408:50Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202410:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202410:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202410:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202410:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202410:38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202410:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
18/10/202410:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
18/10/202407:05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
11/10/202408:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
09/10/202423:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
15/08/202406:25GlobeNewswire Inc.Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
15/08/202406:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
07/08/202422:00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:IKTInhibikase Therapeutics Inc
19/07/202407:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
19/07/202407:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
19/06/202407:27Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
17/06/202422:05GlobeNewswire Inc.Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseNASDAQ:IKTInhibikase Therapeutics Inc
11/06/202406:20Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT